Karolinska Development: Interim Report - January-March 2017
STOCKHOLM - May 16, 2017. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report for the period January - March 2017. The Company will host a conference call and webcast May 17 at 14:00 CEST - details below. The full report is available on the Company's website.
Jim Van heusden, CEO, comments: "I am very proud of what we have achieved at Karolinska Development over the last two years and I am convinced the Company is now in a much stronger position to deliver value as a Nordic life sciences investment company. Given this progress, I believe now is the right time for Viktor Drvota to take over as CEO. With the recent completion of the set-off issue Karolinska Development's equity position and overall financial risk profile has improved. We have also seen our medtech companies make significant commercial progress, particularly in the US, during the first quarter. Combined with the Company's portfolio of exciting therapeutics companies, which are set to deliver a number of value-generating milestones over the next 12-18 months, Karolinska Development is poised to deliver significant value for its shareholders."
Significant events during the first quarter 2017
Karolinska Development launched a set-off issue of shares, decided by the board and subsequently approved by an Extraordinary General Meeting held on 8 March 2017, with the aim of a necessary strengthening of the Company's equity position and thereby improving the Company's overall financial risk profile. The offered subscription price for the set-off issue was SEK 6.17 per new B share and the maximum proceeds of the issue were set at SEK 451 million. Convertible holders accepted to offset SEK 67 million of the company's convertible debt, and as a result, 10,871,698 new B shares have been issued (March 2017).
Karolinska Development's Chief Investment Officer Viktor Drvota was promoted to Deputy Chief Executive Officer (February 2017).
Dilafor initiated a Phase IIb clinical trial with tafoxiparin in women with protracted labor (January 2017).
OssDsign received 510(k) clearance by the US FDA to market OSSDSIGN® Cranial PSI in the US and is preparing to launch the product (January 2017). The company entered an agreement for distribution of OSSDSIGN® Cranial PSI in the US with Matador Medical Inc. (February 2017).
OssDsign entered into new partnerships in Italy, Spain, Switzerland, Austria and the Netherlands for the commercialization of its medical implants for cranial and facial reconstruction, adding to existing partnerships in the UK, Nordic region and certain other non-European markets (January 2017).
Promimic appointed Magnus Larsson as Chief Executive Officer, replacing Ulf Brogren, who relocated to the US to lead Promimic Inc., the Company's new sales operation in North America as Head of Sales (January 2017).
KDev Investments (an investment fund jointly owned by Karolinska Development and Rosetta Capital) divested its entire shareholding in Inhalation Sciences Sweden AB (ISS) to the Swedish investment company Råsunda Förvaltning AB together with two other purchasers. Karolinska Development retains an economic interest in ISS through an earn-out agreement (February 2017).
Oncopeptides made a successful initial public offering ("IPO") on Nasdaq Stockholm. Karolinska Development has a 5% earn-out agreement for Oncopeptides with Industrifonden with a market value of SEK 26.7 million based on Oncopeptide's market capitalization at listing on February 22, 2017. The earn-out will be received when Industrifonden divests its ownership in Oncopeptides.
Umecrine Cognition announced the first patient had been included in its clinical Phase Ib/IIa study with GR3027 for hepatic encephalopathy (March 2017).
Aprea Therapeutics announced a research collaboration with Memorial Sloan Kettering Cancer Center (March 2017).
Significant events after the first quarter 2017
Karolinska Development announced the results of the set-off issue (April 2017)
The Company announced that Chairman Bo Jesper Hansen and CEO Jim Van heusden had decided to step down, and the promotion of Viktor Drvota to CEO (April 2017)
The Company's Nomination Committee proposed that Niclas Adler is elected as new chairman at the General Meeting in May 2017 (April 2017)
Umecrine Cognition presented result from its Phase I study at the EASL International Liver Congress 2017 (April 2017)
Modus Therapeutics announces appointment of Ellen K. Donnelly, Ph.D. as CEO (April 2017)
The Total Portfolio Fair Value of Karolinska Development's portfolio at the end of March 2017 was SEK 431.7 million, an increase from the Total Portfolio Fair Value of SEK 405.2 million at the end of December 2016. Net Portfolio Fair Value at the end of March 2017 was SEK 172.6 million, an increase of SEK 23.2 million compared to the end of December 2016.
The Result of Change in Portfolio Fair Value amounted to SEK -5.7 million. The decrease was mainly due to the reduction in Fair Value of Lipidor following the latest financing round in March 2017, in which Karolinska Development did not participate.
Revenue amounted to SEK 0.6 million in the first quarter (SEK 0.6 million in the first quarter 2016). Net loss amounted to SEK 25.2 million (loss of SEK 100.1 million in first quarter 2016). Earnings per share amounted to SEK -0.5 (SEK -1.9 in first quarter 2016).
Karolinska Development's investments in portfolio companies during the first quarter amounted to SEK 28.9 million. Total investments in portfolio companies by other specialized life science investors during first quarter amounted to SEK 53.1 million.
Cash, cash equivalents and short term liquidity investments decreased by SEK 36.8 million during the first quarter and amounted to SEK 211.3 million as of March 31, 2017.
Following the set-off issue of B-shares, equity in the Parent Company amounted to SEK 46.5 million at the end of March 2017.
Conference Call and Webcast
The Company will host a conference call on May 17, 2017 at 14:00 CEST. Please dial in at one of the following numbers a few minutes before the start of the conference call:
From Sweden: +46 (0) 8 505 564 74
From the US: +1 855 753 22 30
From the UK: +44 (0) 20 336 453 74
The presentation will also be webcast and can be accessed from the following web address:
Host: Jim Van heusden, CEO.
For further information, please contact:
Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09, e-mail: firstname.lastname@example.org
Christian Tange, CFO, Karolinska Development AB
Phone: +46 73 712 14 30, e-mail: email@example.com
David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson
Phone: +44 20 7638 9571; e-mail: KDev@citigatedr.co.uk
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com
This information is information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Jim Van heusden, at 18:00 CEST on May 16th 2017
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
Senegal and France to host Global Partnership for Education Financing Conference20.9.2017 23:00 | Pressmeddelande
NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE) -- The Global Partnership for Education (GPE) is delighted that the governments of Senegal and France will co-host its financing conference, which will take place on February 8, 2018 in Dakar, Senegal. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d3003cff-ee20-409f-9729-9a9cef1d4d3e A video accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0a7eebb6-66b3-438b-904e-efeff83d94cf The announcement of the co-hosting was made by Presidents Macky Sall of Senegal and Emmanuel Macron of France at a high-level event on education financing held at the United Nations, which was attended by Secretary General António Guterres, several heads of state and leaders on global education. " The Global Partnership for Education has made substantial investments in education helpin
K2 Launches New Process Automation Platform Including New Cloud Service20.9.2017 18:00 | Pressmeddelande
K2's process automation platform allows businesses of all types around the globe to rapidly build and deploy automation across the business. BELLEVUE, Wash., Sept. 20, 2017 (GLOBE NEWSWIRE) -- K2 today announced the availability of its new low-code process automation platform - furthering innovation in the way organizations drive digital efficiencies. With a new managed cloud service, K2 Cloud, new on-premises version, K2 Five, and completely redesigned user interfaces and experiences, the platform helps businesses of all types around the globe rapidly deliver powerful process automation and realize business productivity gains. Automating business processes across an enterprise is crucial to the success of companies in the era of digital transformation. However, many initiatives are impacted by a lack of sufficient resources and the use of inefficient systems to manage processes. K2's low-code process automation platform solves these problems by enabling organ
8x8 and Aryaka Partner to Enhance Cloud Communications for Global Enterprises20.9.2017 16:43 | Pressmeddelande
Strategic Alliance will improve communications experience for business users worldwide SAN MATEO, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Aryaka®, the leading global SD-WAN provider, and 8x8, Inc. (NASDAQ:EGHT), the world's first Communications Cloud provider, today announced that they are entering a strategic partnership that will improve the performance and reliability of business-critical cloud unified communications. This will enable global mid-market and enterprise companies to enhance business communications, collaboration and customer engagement for their employees, customers and partners around the world. Through this partnership, Aryaka's global SD-WAN solution will provide enterprise-grade private connectivity to further enhance the superior voice and video quality delivered by the 8x8 Communications Cloud(TM). When tested against several leading Unified Communications as a Service (UCaaS) providers, 8x8 was recently found by the Tolly Group to deliver the hi
NRT Technology Corp and Gaming Payments Innovator Sightline Payments Announce Merger20.9.2017 16:00 | Pressmeddelande
Combination Will Accelerate Innovation in Mobile, Data, Cashless Payments, and Provisional Credit Solutions to the Worldwide Integrated Resort Casino Industry LAS VEGAS, Sept. 20, 2017 (GLOBE NEWSWIRE) -- NRT Technology Corp. ("NRT") a leading provider of integrated ticket redemption and payment services to global casino operators, and Sightline Payments ("Sightline"), developers of the disruptive Play+ platform that's powering the next generation of cashless and mobile gaming payment solutions, announced today an agreement to merge. The company on closing will be named NRT Sightline and will form one of the largest pure play gaming payment technology companies in the world with an equity value of over $300 million. Following the closing of the transaction and subject to regulatory approvals, Sightline's CEO and Founder, Kirk Sanford, will assume the role of President and CEO of NRT Sightline. NRT's current Founder, P
BT and Hitachi Partner to Develop Industrial and Enterprise IOT Solutions20.9.2017 15:00 | Pressmeddelande
Initial Focus on Asset Intelligence and Predictive Maintenance Use Cases LAS VEGAS and LONDON, Sept. 20, 2017 (GLOBE NEWSWIRE) -- BT, one of the world's leading providers of communications services and solutions, and Hitachi Vantara, a wholly owned subsidiary of Hitachi Ltd. (TSE:6501) today announced a global partnership to co-create innovative solutions in the area of industrial and enterprise internet of things (IoT). The partnership aims to drive better business outcomes for global customers, including greater efficiency, productivity and cost savings. The companies will initially focus on exploring and designing asset intelligence and predictive maintenance solutions to deliver the desired outcomes for customers in industry sectors such as manufacturing and transportation. Announced at Hitachi's inaugural user conference, Hitachi NEXT 2017, in Las Vegas today, the partnership unites BT's global network infrastructure, cloud capabiliti
XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer20.9.2017 14:00 | Pressmeddelande
AUSTIN, Texas, Sept. 20, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today its agreement with Cedars-Sinai Medical Center located in Los Angeles, California, whereby XBiotech will provide its interleukin-1 alpha antagonist, MABp1, for a Phase I single arm study evaluating the maximum tolerated dose of Onivyde® (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The study will also assess efficacy using various secondary measures including changes in lean body mass, weight stability, IL-6 levels, overall and progression free survival as well as evaluation of the relationship between treatment tolerance and patient functional status. Andrew Hendifar, M.D., Medical Oncology lead for the Gastrointestinal Disease Research Group at Cedars-Sinai and Co-Director of Pancreas Oncology, will be leading the study which is planned to enroll a total of 16 pati
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum